Leap Therapeutics, INC Form 4 insider transactions

Christine Granfield, VP, Head of Regulatory Affairs/Quality at Leap Therapeutics, was granted stock options for 85,000 shares on October 2, 2024.

Cynthia Sirard, Chief Medical Officer of Leap Therapeutics, was granted stock options for 85,000 shares on October 2, 2024, according to a Form 4 filing.

Director Richard Schilsky reports acquisition of 25,000 stock options in Leap Therapeutics, Inc.

Christian M. Richard, a director of Leap Therapeutics, acquired stock options for 25,000 shares on October 2, 2024.

Patricia Martin, a director at Leap Therapeutics, acquired 25,000 stock options on October 2, 2024, according to a recent SEC filing.

Douglas Onsi, CEO, CFO, President, General Counsel, Treasurer, and Secretary of Leap Therapeutics, Inc., was granted 170,000 employee stock options on October 2, 2024.

Director Joseph Loscalzo acquired 25,000 stock options in Leap Therapeutics, Inc. on October 2, 2024.

Director William Li acquired 25,000 stock options in Leap Therapeutics, Inc. on October 2, 2024, according to a recent SEC filing.

John Mark O'Mahony, Chief Manufacturing Officer of Leap Therapeutics, was granted stock options for 85,000 shares on October 2, 2024.

Augustine Lawlor, COO of Leap Therapeutics, reports the acquisition of stock options.

Director Thomas Dietz acquired 30,000 stock options in Leap Therapeutics on October 2, 2024, according to a Form 4 filing.

Director James Cavanaugh acquired 25,000 stock options in Leap Therapeutics, Inc. on October 2, 2024, according to a Form 4 filing with the SEC.

Christopher Mirabelli, a director at Leap Therapeutics, acquired stock options for 85,000 shares on October 2, 2024.

Jason Baum, Chief Scientific Officer of Leap Therapeutics, acquired 85,000 stock options on October 2, 2024, according to a Form 4 filing with the SEC.

Director Nissim Mashiach acquired 25,000 stock options in Leap Therapeutics, Inc. on October 2, 2024, according to a Form 4 filing.